A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors
Study of Safety of New Investigational Study Drug Alone and with Nivolumab in Advanced Solid Tumors
Sponsor: Bristol-Myers Squibb
Enrolling: Male and Female Patients
IRB Number: AAAR6275
U.S. Govt. ID: NCT03369223
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of the study is to test the safety of an investigational study drug called BMS-986249. BMS-986249 will be given alone and in combination with nivolumab. This study will investigate how patients with advanced solid tumors tolerate these drugs. The study will identify the highest dose or most suitable dose of BMS-986249 alone and in combination with nivolumab. This is the first study in which BMS-986249 will be given to humans.
This study is closed
Investigator
Mark Stein, MD
Do You Qualify?
Do you have a solid tumor that continues to spread, has come back, or cannot be removed completely by surgery? Yes No
Are you able to walk, care for yourself, and do light physical activities? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE